Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.
Department of Physical and Analytical Chemistry, University of Oviedo, Asturias, Spain.
J Nanobiotechnology. 2018 May 2;16(1):47. doi: 10.1186/s12951-018-0372-z.
Tumour-derived exosomes can be released to serum and provide information on the features of the malignancy, however, in order to perform systematic studies in biological samples, faster diagnostic techniques are needed, especially for detection of low abundance proteins. Most human cancer cells are positive for at least one ligand for the activating immune receptor NKG2D and the presence in plasma of NKG2D-ligands can be associated with prognosis.
Using MICA as example of a tumour-derived antigen, endogenously expressed in metastatic melanoma and recruited to exosomes, we have developed two immunocapture-based assays for detection of different epitopes in nanovesicles. Although both techniques, enzyme-linked immunosorbent assay (ELISA) and Lateral flow immunoassays (LFIA) have the same theoretical basis, that is, using capture and detection antibodies for a colorimetric read-out, analysis of exosome-bound proteins poses methodological problems that do not occur when these techniques are used for detection of soluble molecules, due to the presence of multiple epitopes on the vesicle.
Here we demonstrate that, in ELISA, the signal obtained was directly proportional to the amount of epitopes per exosome. In LFIA, the amount of detection antibody immobilized in Au-nanoparticles needs to be low for efficient detection, otherwise steric hindrance results in lower signal. We describe the conditions for detection of MICA in exosomes and prove, for the first time using both techniques, the co-existence in one vesicle of exosomal markers (the tetraspanins CD9, CD63 and CD81) and an endogenously expressed tumour-derived antigen. The study also reveals that scarce proteins can be used as targets for detection antibody in LFIA with a better result than very abundant proteins and that the conditions can be optimized for detection of the protein in plasma.
These results open the possibility of analyzing biological samples for the presence of tumour-derived exosomes using high throughput techniques.
肿瘤来源的外泌体可以释放到血清中,并提供关于恶性肿瘤特征的信息,然而,为了在生物样本中进行系统研究,需要更快的诊断技术,特别是用于检测低丰度蛋白质。大多数人类癌细胞至少有一种激活免疫受体 NKG2D 的配体阳性,并且血浆中存在 NKG2D 配体与预后相关。
以肿瘤衍生抗原 MICA 为例,其在转移性黑色素瘤中内源性表达并募集到外泌体中,我们开发了两种基于免疫捕获的检测纳米囊泡中不同表位的方法。尽管这两种技术,酶联免疫吸附试验(ELISA)和侧向流动免疫分析(LFIA)具有相同的理论基础,即使用捕获和检测抗体进行比色读取,但由于囊泡上存在多个表位,分析外泌体结合蛋白会出现这些技术用于检测可溶性分子时不会出现的方法学问题。
在这里,我们证明在 ELISA 中,获得的信号与每个外泌体的表位数量成正比。在 LFIA 中,需要将固定在 Au 纳米颗粒中的检测抗体的量保持低水平,以实现有效的检测,否则空间位阻会导致信号降低。我们描述了在 LFIA 中检测外泌体中 MICA 的条件,并首次使用这两种技术证明了一种囊泡中共存的外泌体标志物(四跨膜蛋白 CD9、CD63 和 CD81)和一种内源性表达的肿瘤衍生抗原。该研究还表明,稀有蛋白质可以作为 LFIA 中检测抗体的靶标,效果优于非常丰富的蛋白质,并且可以优化条件以检测血浆中的蛋白质。
这些结果为使用高通量技术分析生物样本中肿瘤衍生外泌体的存在提供了可能性。